Filing Details
- Accession Number:
- 0001079973-24-000208
- Form Type:
- 13G Filing
- Publication Date:
- 2024-02-08 19:00:00
- Filed By:
- L1 Capital Global Opportunities Master Fund, Ltd.
- Company:
- Zyversa Therapeutics Inc.
- Filing Date:
- 2024-02-09
- SEC Url:
- 13G Filing
Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.
Name | Sole Voting Power | Shared Voting Power | Sole Dispositive Power | Shared Dispositive Power | Aggregate Amount Owned Power | Percent of Class |
---|---|---|---|---|---|---|
L1 Capital Global Opportunities Master Fund Ltd | 0 | 0 | 0 | 0% |
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Amendment No. 1
Under the Securities Exchange Act of 1934
ZyVersa Therapeutics, Inc. |
(Name of Issuer) |
Common Stock, $0.0001 per share |
(Title of Class of Securities) |
98987D 102 |
(CUSIP Number) |
December 31, 2023 |
(Date of Event Which Requires Filing of this Statement) |
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
☐ Rule 13d-1(b)
☒ Rule 13d-1(c)
☐ Rule 13d-1(d)
*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities and Exchange Act of 1934 (the “Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
CUSIP No. 98987D 102 | 13G/A | Page 2 of 5 Pages |
1 | NAME OF REPORTING PERSONS | ||
L1 Capital Global Opportunities Master Fund Ltd. | |||
2 | CHECK THE APPROPRIATE BOX IF MEMBER OF A GROUP | ||
(a) ☐ | |||
(b) ☐ | |||
3 | SEC USE ONLY | ||
4 | CITIZENSHIP OR PLACE OF ORGANIZATION | ||
Cayman Islands | |||
5 | SOLE VOTING POWER | ||
0 | |||
NUMBER OF | 6 | SHARED VOTING POWER | |
SHARES | |||
BENEFICIALLY | 0 | ||
OWNED BY | 7 | SOLE DISPOSITIVE POWER | |
EACH REPORTING | |||
PERSON WITH | 0 | ||
8 | SHARED DISPOSITIVE POWER | ||
0 | |||
9 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON | ||
0 | |||
10 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES | ||
☐ | |||
11 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) | ||
0% | |||
12 | TYPE OF REPORTING PERSON | ||
FI | |||
CUSIP No. 98987D 102 | 13G/A | Page 3 of 5 Pages |
Item 1. Security and Issuer.
(a) | Name of Issuer: |
ZyVersa Therapeutics, Inc.
(b) |
Address of Issuer: |
2200 N. Commerce Parkway, Suite 208, Weston, FL 33326
Item 2. Identity and Background.
(a) | Name of Person Filing: |
L1 Capital Global Opportunities Master Fund, Ltd. | |
(b) | Address of Principal Business Office or, if none, Residence: |
161A Shedden Road, 1 Artillery Court PO Box 10085 Grand Cayman, Cayman Islands KY1-1001 | |
(c) | Citizenship or Place of Organization: |
Cayman Islands | |
(d) | Title of Class of Securities: |
Common Stock, par value $0.0001 per share. | |
(e) | CUSIP Number: |
98987D 102 |
Item 3.
Not applicable.
CUSIP No. 98987D 102 | 13G/A | Page 4 of 5 Pages |
Item 4. Ownership.
(a)-(c) | The information required by Items 4(a)-(c) is set forth in Rows (5)-(9) and Row (11) of the cover page and is incorporated herein by reference. |
The percentage set forth on Row (11) of the cover page for the reporting person is based on 43,519,719 shares of common stock outstanding as of November 10, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 14, 2023. |
Item 5. | Ownership of 5 Percent or Less of a Class.
If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following þ |
Item 6. | Ownership of More than 5 Percent on Behalf of Another Person. |
Not applicable.
Item 7. | Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person. |
Not applicable.
Item 8. | Identification and Classification of Members of the Group. |
Not applicable.
Item 9. | Notice of Dissolution of Group. |
Not applicable.
Item 10. | Certifications.
|
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the Issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
CUSIP No. 98987D 102 | 13G/A | Page 5 of 5 Pages |
SIGNATURES
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete, and correct.
By: | L1 Capital Global Opportunities Master Fund Ltd. | |
February 9, 2024 | By: | /s/ David Feldman |
David Feldman, Director |